{
    "2021-07-29": [
        [
            {
                "time": "",
                "original_text": "贝达药业CTLA-4抗体联合PD-1抗体治疗晚期宫颈癌获批开展临床试验",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "CTLA-4抗体",
                        "PD-1抗体",
                        "晚期宫颈癌",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：泽弗利单抗注射液联合巴替利单抗注射液治疗晚期宫颈癌获临床试验批准",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "泽弗利单抗注射液",
                        "巴替利单抗注射液",
                        "晚期宫颈癌",
                        "临床试验批准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}